论文部分内容阅读
糖尿病(DM)是全球范围内影响居民健康的主要慢性病之一,根据2015年国际糖尿病联盟(IDF)数据显示,全世界已有4.15亿糖尿病患者[1],其心脑血管、视网膜等并发症严重威胁和影响患者的生命及生存质量,增加了全球疾病负担;第六次全国糖尿病流行病学调查显示,中国成年人糖尿病患病率高达11.6%[1]。非对称二甲基精氨酸(ADMA)存在于人体血清中,是一种内源性的非选择性的内皮一氧化氮合酶(NOS)抑制剂,限制一氧化氮(NO)的
Diabetes mellitus (DM) is one of the major chronic diseases affecting the health of residents worldwide. According to the 2015 IDF data, 415 million people with diabetes worldwide [1] have cardiovascular, retinal and other complications A serious threat to and affect the patient’s life and quality of life, increasing the global burden of disease; the sixth national epidemiological survey of diabetes showed that the prevalence of diabetes in Chinese adults as high as 11.6% [1]. Asymmetric dimethylarginine (ADMA) is present in human serum and is an endogenous non-selective inhibitor of endothelial nitric oxide synthase (NOS) that limits nitric oxide (NO)